See more : Concrete Leveling Systems, Inc. (CLEV) Income Statement Analysis – Financial Results
Complete financial analysis of BCWORLD PHARM. Co., Ltd. (200780.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BCWORLD PHARM. Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- SKAGEN – Kon-Tiki (SKIKON.CO) Income Statement Analysis – Financial Results
- Gooch & Housego PLC (GHH.L) Income Statement Analysis – Financial Results
- Bank of Chongqing Co., Ltd. (1963.HK) Income Statement Analysis – Financial Results
- Glow Lifetech Corp. (GLOW.CN) Income Statement Analysis – Financial Results
- Ballistic Recovery Systems Inc. (BRSI) Income Statement Analysis – Financial Results
BCWORLD PHARM. Co., Ltd. (200780.KQ)
About BCWORLD PHARM. Co., Ltd.
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory. BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75.11B | 72.70B | 62.08B | 57.03B | 51.50B | 54.79B | 50.21B | 45.66B | 41.41B |
| Cost of Revenue | 43.23B | 48.52B | 42.87B | 40.71B | 34.77B | 33.74B | 26.65B | 23.31B | 20.71B |
| Gross Profit | 31.88B | 24.18B | 19.21B | 16.32B | 16.73B | 21.05B | 23.56B | 22.35B | 20.71B |
| Gross Profit Ratio | 42.44% | 33.26% | 30.95% | 28.62% | 32.49% | 38.42% | 46.93% | 48.96% | 50.01% |
| Research & Development | 1.20B | 7.55B | 8.66B | 10.43B | 7.75B | 6.72B | 6.21B | 6.17B | 5.52B |
| General & Administrative | 5.01B | 6.78B | 2.83B | 2.52B | 250.81M | 187.99M | 185.40M | 190.02M | 0.00 |
| Selling & Marketing | 3.57B | 3.45B | 1.71B | 1.25B | 848.79M | 879.98M | 791.99M | 1.92B | 0.00 |
| SG&A | 8.58B | 14.71B | 11.88B | 7.11B | 9.84B | 8.70B | 8.46B | 9.26B | 8.57B |
| Other Expenses | 15.82B | -58.84M | -200.34M | -219.58M | -141.95M | -24.85M | -12.73M | -8.29M | -4.62M |
| Operating Expenses | 25.60B | 22.32B | 20.74B | 17.76B | 17.74B | 15.45B | 14.69B | 15.44B | 14.09B |
| Cost & Expenses | 68.75B | 70.84B | 63.61B | 58.47B | 52.50B | 49.19B | 41.33B | 38.75B | 34.80B |
| Interest Income | 179.85M | 63.45M | 33.39M | 220.19M | 75.63M | 139.33M | 234.33M | 170.56M | 257.62M |
| Interest Expense | 5.23B | 3.79B | 2.17B | 2.42B | 2.38B | 234.03M | 259.08M | 214.72M | 110.13M |
| Depreciation & Amortization | 7.47B | 7.26B | 5.58B | 4.54B | 3.66B | 3.40B | 2.61B | 1.74B | 1.38B |
| EBITDA | 13.91B | 9.53B | 4.82B | 4.12B | 2.43B | 9.12B | 11.44B | 8.68B | 7.51B |
| EBITDA Ratio | 18.52% | 12.55% | 6.52% | 5.43% | 5.15% | 16.42% | 22.88% | 18.94% | 19.30% |
| Operating Income | 6.37B | 1.86B | -1.53B | -1.44B | -1.00B | 5.60B | 8.87B | 6.91B | 6.62B |
| Operating Income Ratio | 8.47% | 2.56% | -2.47% | -2.53% | -1.95% | 10.22% | 17.67% | 15.14% | 15.97% |
| Total Other Income/Expenses | -5.16B | -3.38B | -1.40B | -1.39B | -1.57B | -113.19M | -305.92M | -181.42M | -593.41M |
| Income Before Tax | 1.21B | -1.52B | -2.94B | -2.83B | -2.57B | 5.49B | 8.57B | 6.73B | 6.02B |
| Income Before Tax Ratio | 1.61% | -2.09% | -4.73% | -4.96% | -4.99% | 10.02% | 17.07% | 14.74% | 14.54% |
| Income Tax Expense | -1.69B | -1.58B | 42.06M | -635.66M | -833.04M | 520.35M | 502.90M | 254.69M | -304.14M |
| Net Income | 2.63B | 281.30M | -1.84B | -1.58B | -1.55B | 4.99B | 8.08B | 6.47B | 6.33B |
| Net Income Ratio | 3.51% | 0.39% | -2.97% | -2.77% | -3.02% | 9.11% | 16.10% | 14.18% | 15.28% |
| EPS | 312.11 | 33.01 | -215.85 | -185.68 | -183.57 | 590.22 | 955.69 | 833.83 | 747.93 |
| EPS Diluted | 312.11 | 33.01 | -215.85 | -185.68 | -183.57 | 590.22 | 943.30 | 830.49 | 747.93 |
| Weighted Avg Shares Out | 8.44M | 8.52M | 8.54M | 8.51M | 8.46M | 8.46M | 8.46M | 7.77M | 8.46M |
| Weighted Avg Shares Out (Dil) | 8.44M | 8.52M | 8.54M | 8.51M | 8.46M | 8.46M | 8.57M | 7.80M | 8.46M |
Source: https://incomestatements.info
Category: Stock Reports